UBS Group AG Sells 261,028 Shares of Sana Biotechnology, Inc. $SANA

UBS Group AG lowered its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 18.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,182,958 shares of the company’s stock after selling 261,028 shares during the quarter. UBS Group AG’s holdings in Sana Biotechnology were worth $4,815,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Baillie Gifford & Co. raised its stake in shares of Sana Biotechnology by 13.6% in the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares during the period. Vanguard Group Inc. raised its stake in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after buying an additional 1,517,474 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares during the period. Integral Health Asset Management LLC raised its stake in shares of Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after buying an additional 500,000 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Sana Biotechnology by 103.1% in the third quarter. Millennium Management LLC now owns 1,620,000 shares of the company’s stock worth $5,751,000 after buying an additional 822,423 shares during the period. Institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 target price for the company. HC Wainwright cut their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Finally, Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Trading Up 1.3%

NASDAQ:SANA opened at $3.15 on Friday. Sana Biotechnology, Inc. has a 12-month low of $1.81 and a 12-month high of $6.55. The stock has a 50-day moving average price of $3.24 and a 200 day moving average price of $3.89. The stock has a market capitalization of $876.61 million, a P/E ratio of -3.39 and a beta of 2.17.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. On average, research analysts predict that Sana Biotechnology, Inc. will post -0.62 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.